Align Technology (ALGN)


Market Price (8/19/2026): $168.3 | Market Cap: $12.0 BilInvestor Relations Sector: Health Care | Industry: Health Care Supplies

Align Technology (ALGN)


Market Price (8/19/2026): $168.3
Market Cap: $12.0 Bil
Sector: Health Care
Industry: Health Care Supplies

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

0

Attractive cash flow generation
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 18%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 15%

Attractive yield
FCF Yield is 5.3%

Stock buyback support
Stock Buyback 3Y Total is 1.2 Bil

Low stock price volatility
Vol 12M is 40%

Megatrend and thematic drivers
Megatrends include Precision Medicine, and Digital Health & Telemedicine. Themes include Personalized Diagnostics, Remote Patient Monitoring, Show more.

Weak multi-year price returns
2Y Excs Rtn is -65%, 3Y Excs Rtn is -125%

Expensive valuation multiples
P/EPrice/Earnings or Price/(Net Income) is 29x

Key risks
ALGN key risks include [1] intensified competition and pricing pressure following the expiration of its key patents and [2] costly intellectual property litigation and regulatory scrutiny.

0 Attractive cash flow generation
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 18%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 15%
1 Attractive yield
FCF Yield is 5.3%
2 Stock buyback support
Stock Buyback 3Y Total is 1.2 Bil
3 Low stock price volatility
Vol 12M is 40%
4 Megatrend and thematic drivers
Megatrends include Precision Medicine, and Digital Health & Telemedicine. Themes include Personalized Diagnostics, Remote Patient Monitoring, Show more.
5 Weak multi-year price returns
2Y Excs Rtn is -65%, 3Y Excs Rtn is -125%
6 Expensive valuation multiples
P/EPrice/Earnings or Price/(Net Income) is 29x
7 Key risks
ALGN key risks include [1] intensified competition and pricing pressure following the expiration of its key patents and [2] costly intellectual property litigation and regulatory scrutiny.

ALGN in ETFs

Weight = ALGN's share of each fund

SPY0.02%
VOO0.02%
IVV0.02%
VTI0.02%
ITOT0.02%
IWB0.02%
RSP0.20%
VB0.14%
+24 more covered ETFs

Valuation & Metrics

Price Chart

Why The Stock Moved

Qualitative Assessment

AI Analysis | Feedback

Updated on 8/17/2026

Align Technology (ALGN) stock has lost about 5% since 4/30/2026 because of the following key factors:

1. Align Technology's stock experienced downward pressure following its second quarter fiscal year 2026 (Q2 2026) earnings report on July 29, 2026, which included guidance for softer third quarter revenue and one-time restructuring charges. Despite reporting Q2 2026 earnings per share of $2.64, which beat analyst expectations, the stock declined by 3.70% on July 30, 2026, the day after the earnings announcement.

2. The company's Systems & Services segment demonstrated weakness, with revenue declining 10.8% year-over-year in Q2 2026. This decrease primarily reflected a strategic shift by Align Technology toward lower-priced scanner options, leasing, and rentals, impacting overall revenue growth for the segment.

Show more
Updated on 8/17/2026

Align Technology (ALGN) stock has lost about 5% since 4/30/2026 because of the following key factors:

1. Align Technology's stock experienced downward pressure following its second quarter fiscal year 2026 (Q2 2026) earnings report on July 29, 2026, which included guidance for softer third quarter revenue and one-time restructuring charges. Despite reporting Q2 2026 earnings per share of $2.64, which beat analyst expectations, the stock declined by 3.70% on July 30, 2026, the day after the earnings announcement.

2. The company's Systems & Services segment demonstrated weakness, with revenue declining 10.8% year-over-year in Q2 2026. This decrease primarily reflected a strategic shift by Align Technology toward lower-priced scanner options, leasing, and rentals, impacting overall revenue growth for the segment.

3. Align Technology faced increased operating expenses in Q2 2026, which rose by 10.7% compared to the previous year. This increase was attributed to factors such as UK VAT accrual, higher employee salaries, and costs associated with expanding the systems and services business, impacting the company's profitability.

4. Ongoing concerns regarding market saturation and heightened competition in both the clear aligner and intraoral scanner markets continued to temper investor sentiment. Analysts highlighted Align Technology's heavy reliance on its Invisalign product and increasing competition in the digital scanning segment, posing challenges to maintaining market dominance and sustained long-term growth.

5. Analyst sentiment for ALGN showed a slight moderation during the period, with the average recommendation score slipping from 4.27 to 4.19 out of 5.0, reflecting increased caution. Although the consensus remained a "Moderate Buy," this shift suggests a reassessment of the company's near-term outlook among some analysts.

Show less
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →

Stock Movement Drivers

Fundamental Drivers

The -4.6% change in ALGN stock from 4/30/2026 to 8/18/2026 was primarily driven by a -5.6% change in the company's P/E Multiple.
(LTM values as of)43020268182026Change
Stock Price ($)176.01167.91-4.6%
Change Contribution By: 
Total Revenues ($ Mil)4,0354,1402.6%
Net Income Margin (%)10.2%10.0%-1.8%
P/E Multiple30.729.0-5.6%
Shares Outstanding (Mil)72710.3%
Cumulative Contribution-4.6%

LTM = Last Twelve Months as of date shown

Market Drivers

4/30/2026 to 8/18/2026
ReturnCorrelation
ALGN-4.6% 
Market (SPY)6.8%30.1%
Sector (XLV)16.3%31.0%

Fundamental Drivers

The 3.0% change in ALGN stock from 1/31/2026 to 8/18/2026 was primarily driven by a 5.2% change in the company's Net Income Margin (%).
(LTM values as of)13120268182026Change
Stock Price ($)163.03167.913.0%
Change Contribution By: 
Total Revenues ($ Mil)3,9834,1403.9%
Net Income Margin (%)9.5%10.0%5.2%
P/E Multiple31.229.0-6.9%
Shares Outstanding (Mil)72711.2%
Cumulative Contribution3.0%

LTM = Last Twelve Months as of date shown

Market Drivers

1/31/2026 to 8/18/2026
ReturnCorrelation
ALGN3.0% 
Market (SPY)11.2%43.9%
Sector (XLV)10.1%33.6%

Fundamental Drivers

The 30.2% change in ALGN stock from 7/31/2025 to 8/18/2026 was primarily driven by a 25.3% change in the company's P/E Multiple.
(LTM values as of)73120258182026Change
Stock Price ($)129.01167.9130.2%
Change Contribution By: 
Total Revenues ($ Mil)3,9814,1404.0%
Net Income Margin (%)10.3%10.0%-2.9%
P/E Multiple23.229.025.3%
Shares Outstanding (Mil)74712.9%
Cumulative Contribution30.2%

LTM = Last Twelve Months as of date shown

Market Drivers

7/31/2025 to 8/18/2026
ReturnCorrelation
ALGN30.2% 
Market (SPY)22.4%42.6%
Sector (XLV)31.8%37.1%

Fundamental Drivers

The -55.6% change in ALGN stock from 7/31/2023 to 8/18/2026 was primarily driven by a -68.5% change in the company's P/E Multiple.
(LTM values as of)73120238182026Change
Stock Price ($)377.89167.91-55.6%
Change Contribution By: 
Total Revenues ($ Mil)3,7054,14011.7%
Net Income Margin (%)8.5%10.0%17.5%
P/E Multiple92.329.0-68.5%
Shares Outstanding (Mil)77717.6%
Cumulative Contribution-55.6%

LTM = Last Twelve Months as of date shown

Market Drivers

7/31/2023 to 8/18/2026
ReturnCorrelation
ALGN-55.6% 
Market (SPY)73.6%46.2%
Sector (XLV)32.5%37.1%

Return vs. Risk

Price Returns Compared

 202120222023202420252026Total [1]
Returns
ALGN Return23%-68%30%-24%-25%10%-68%
Peers Return41%-33%-9%-31%-15%37%-30%
S&P 500 Return27%-19%24%23%16%13%106%

Monthly Win Rates [3]
ALGN Win Rate50%33%58%42%67%62% 
Peers Win Rate50%40%48%42%42%66% 
S&P 500 Win Rate75%42%67%75%67%50% 

Max Drawdowns [4]
ALGN Max Drawdown-20%-73%-52%-38%-47%-21% 
Peers Max Drawdown-33%-47%-47%-46%-45%-28% 
S&P 500 Max Drawdown-5%-25%-10%-8%-19%-9% 


[1] Cumulative total returns since the beginning of 2021
[2] Peers: NVST, XRAY, HSIC, DDD. See ALGN Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 8/18/2026 (YTD)

How Low Can It Go

EventALGNS&P 500
2025 US Tariff Shock
  % Loss-28.5%-18.8%
  % Gain to Breakeven39.8%23.1%
  Time to Breakeven93 days79 days
2024 Yen Carry Trade Unwind
  % Loss-18.1%-7.8%
  % Gain to Breakeven22.1%8.5%
  Time to Breakeven40 days18 days
2023 SVB Regional Banking Crisis
  % Loss-13.9%-6.7%
  % Gain to Breakeven16.1%7.1%
  Time to Breakeven21 days31 days
2020 COVID-19 Crash
  % Loss-50.3%-33.7%
  % Gain to Breakeven101.2%50.9%
  Time to Breakeven74 days140 days
Q4 2018 Fed Policy Error / Growth Scare
  % Loss-50.8%-19.2%
  % Gain to Breakeven103.1%23.8%
  Time to Breakeven658 days105 days
2016-2017 Trump Reflation Bond Selloff
  % Loss-11.1%-3.7%
  % Gain to Breakeven12.4%3.9%
  Time to Breakeven21 days6 days

Compare to NVST, XRAY, HSIC, DDD

In The Past

Align Technology's stock fell -28.5% during the 2025 US Tariff Shock. Such a loss loss requires a 39.8% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

EventALGNS&P 500
2025 US Tariff Shock
  % Loss-28.5%-18.8%
  % Gain to Breakeven39.8%23.1%
  Time to Breakeven93 days79 days
2020 COVID-19 Crash
  % Loss-50.3%-33.7%
  % Gain to Breakeven101.2%50.9%
  Time to Breakeven74 days140 days
Q4 2018 Fed Policy Error / Growth Scare
  % Loss-50.8%-19.2%
  % Gain to Breakeven103.1%23.8%
  Time to Breakeven658 days105 days
2011 US Debt Ceiling Crisis & European Contagion
  % Loss-40.6%-17.9%
  % Gain to Breakeven68.4%21.8%
  Time to Breakeven58 days123 days
2010 Eurozone Sovereign Debt Crisis / Flash Crash
  % Loss-22.6%-15.4%
  % Gain to Breakeven29.2%18.2%
  Time to Breakeven47 days125 days
2008-2009 Global Financial Crisis
  % Loss-72.5%-53.4%
  % Gain to Breakeven263.0%114.4%
  Time to Breakeven438 days1085 days

Compare to NVST, XRAY, HSIC, DDD

In The Past

Align Technology's stock fell -28.5% during the 2025 US Tariff Shock. Such a loss loss requires a 39.8% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Align Technology (ALGN)

Align Technology, Inc. (ALGN) is a global medical device company that innovates in digital dentistry, primarily known for its clear aligner solutions and advanced intraoral scanning technology. The company designs, manufactures, and markets products that transform orthodontic and restorative dental treatments.

Its core offering is the Invisalign system, a comprehensive suite of custom-made clear aligners that serve as an aesthetic and often more comfortable alternative to traditional metal braces. Invisalign treatments cater to a wide range of patients, from young children needing early intervention to teenagers and adults requiring full orthodontic correction. Complementing the aligners, Align Technology also provides retention products, professional training, and various ancillary treatment tools.

The company's other significant segment includes its iTero intraoral scanners and associated services. These high-precision scanners create digital 3D images of teeth, eliminating the need for traditional dental impressions. The iTero platform is supported by sophisticated software for orthodontic diagnosis, treatment planning, and restorative procedures, including tools for outcome simulation and progress assessment. Align Technology primarily serves orthodontists, general practitioner dentists, and other dental specialists globally, empowering them to deliver modern digital dental care.

AI Analysis | Feedback

1. Tesla for teeth straightening

2. Apple for orthodontics

AI Analysis | Feedback

  • Invisalign Clear Aligners: A comprehensive line of transparent, removable aligners designed for orthodontic treatment across various age groups and complexities.
  • iTero Intraoral Scanners: Advanced digital scanning hardware platforms that capture 3D images of teeth and gums for use in restorative and orthodontic procedures.
  • iTero Software Solutions: Specialized software applications for iTero scanners, providing functionalities for restorative dentistry, orthodontic diagnosis, digital record storage, and model/retainer fabrication.
  • Dental CAD/CAM Services: Computer-aided design and manufacturing services supporting the fabrication of various dental appliances and models.
  • Invisalign Ancillary Products & Training: Includes retention products, cleaning materials, adjusting tools, and professional training fees for dental practitioners utilizing the Invisalign system.
  • iTero Ancillary Products & Digital Tools: Consists of disposable scanner sleeves, models and dies, and digital applications such as the Invisalign Outcome Simulator, Progress Assessment tool, and TimeLapse technology.

AI Analysis | Feedback

Align Technology (ALGN) primarily sells its products and services to other businesses, specifically dental professionals and their practices, rather than directly to individual consumers. The company's major customers are not large, publicly traded companies that can be listed by name and symbol. Instead, Align Technology serves a broad base of dental professionals who operate their own clinics and practices.

The categories of dental professionals that Align Technology serves are:

  1. Orthodontists: Specialists who diagnose, prevent, and treat dental and facial irregularities. They are key users of Invisalign clear aligners and iTero intraoral scanners for orthodontic procedures and digital records.
  2. General Practitioner Dentists (GPs): Dentists who provide primary dental care, including restorative and aesthetic dentistry. They utilize Invisalign for moderate, lite, and express treatments, as well as iTero scanners for restorative procedures.
  3. Other Dental Specialists: This category includes professionals such as prosthodontists (specializing in dental prosthetics), periodontists (specializing in gum health), and oral surgeons, who use iTero intraoral scanners and associated software for restorative procedures, digital records, and treatment planning.

AI Analysis | Feedback

null

AI Analysis | Feedback

Joseph M. Hogan, President and Chief Executive Officer

Joseph M. Hogan joined Align Technology in June 2015 as President, Chief Executive Officer (CEO), and a Director. Mr. Hogan is an accomplished executive with extensive experience across multiple industries, including healthcare, technology, and industrial automation. Before joining Align, he served as CEO of ABB, a global power and automation technologies company, where he oversaw a 25% increase in revenues during his five-year tenure. Prior to ABB, Mr. Hogan spent 25 years at General Electric (GE) in various executive and management roles, including eight years as CEO of GE Healthcare. At GE Healthcare, he significantly expanded geographic and market portfolios, more than doubling revenues from $7 billion to $16 billion. He earned an M.B.A. from Robert Morris University and a B.S. degree in Business and Economics from Geneva College.

John F. Morici, Chief Financial Officer and Executive Vice President, Global Finance

John F. Morici joined Align Technology in November 2016 as Chief Financial Officer (CFO) and Executive Vice President of Global Finance. He is responsible for managing the company's global finance and financial strategy. With over two decades of experience, Mr. Morici has held senior leadership positions in finance, operations, and strategic planning within healthcare, medical technology, and consumer/entertainment sectors. Before Align, he spent nine years at NBC Universal, where he held several senior management positions in its Universal Pictures Home Entertainment U.S. and Canadian businesses, including CFO, COO, and Executive Vice President and Managing Director. In his role as Executive Vice President and Managing Director at NBC Universal, he led all finance, sales, marketing, operations, and customer service organizations, and was responsible for overall strategy and planning. Prior to NBC Universal, Mr. Morici spent eight years in senior financial management positions at GE Healthcare, serving as CFO for its Diagnostic Imaging and Global Products units. He also held financial management roles at Case New Holland and Abbott Laboratories. Mr. Morici holds an M.B.A. in Finance and a B.S. in Molecular Biology, both from the University of Wisconsin.

Julie Coletti, Executive Vice President, Chief Legal and Regulatory Officer

Julie Coletti is the Executive Vice President, Chief Legal and Regulatory Officer of Align Technology, leading the company's global legal, regulatory, and quality teams. She also serves as corporate secretary to Align Technology Inc.'s Board of Directors. Ms. Coletti joined Align in May 2018 as Vice President, Associate General Counsel, Strategic Commercial Affairs, and was promoted to her current position in May 2019. She is an experienced life sciences and technology executive, general counsel, and chief compliance officer. Before Align, she served as Vice President and Global General Counsel of Danaher Corporation's $3 billion dental medical device platform. Prior to Danaher, she was Vice President, Chief Legal Officer, and Corporate Secretary at Bayer HealthCare's MEDRAD/Radiology and Interventional Division. Ms. Coletti began her career in litigation at LeBoeuf, Lamb, Greene & MacRae LLP. She received her J.D. from the University of Pittsburgh and her B.A. from Rutgers University. She also serves as a director for Fortis Life Sciences.

Raj Pudipeddi, Executive Vice President, Chief Product & Marketing Officer and Managing Director, Asia Pacific

Raj Pudipeddi joined Align Technology in 2019 as Senior Vice President and Chief Marketing Officer. In his current dual roles, he has global responsibility for product, marketing, innovation, business development, and clinical teams, as well as for the market development and commercial execution of all Align Technology products and services in the Asia Pacific region. Mr. Pudipeddi possesses 26 years of business leadership and brand-building experience across consumer goods and telecom. He began his career at Procter & Gamble, where he spent nearly 22 years in various leadership roles across businesses in North America, Asia, and Latin America. Most recently, before joining Align, he served as Chief Marketing Officer and Director, Consumer Business at Bharti Airtel, an Indian telecom leader. Mr. Pudipeddi earned an M.B.A. degree from the Indian Institute of Management, Lucknow, and a Bachelor of Engineering degree from the Gandhi Institute of Technology. He is also an Independent Director at Sonendo, Inc. and a Board Advisor at Spark Venture Capital LLC.

Stuart Hockridge, Executive Vice President, Global Human Resources

Stuart Hockridge serves as the Executive Vice President, Global Human Resources at Align Technology. He started at Align Technology in May 2016. Prior to Align, Mr. Hockridge held senior leadership roles in human resources for global companies.

AI Analysis | Feedback

The key risks to Align Technology's business include intense competition and pricing pressure, macroeconomic sensitivity affecting demand, and ongoing intellectual property and litigation challenges.

The orthodontic industry is characterized by **intense competition and pricing pressure**. Align Technology faces significant competition from established dental companies like 3M Company, Dentsply Sirona Inc., and Danaher Corporation, which offer traditional orthodontic products and alternative clear aligner systems such as Clarity Aligners and SureSmile aligners. New entrants, including direct-to-consumer companies and those offering 3D printing alternatives, also contribute to a highly competitive landscape. This competitive environment has led to pricing pressure, resulting in a decline in the Average Selling Price (ASP) for Align's clear aligner products and impacting its overall profitability. The company has responded by shifting towards lower-priced, non-comprehensive aligner options, which further compresses margins.

Align Technology is highly susceptible to **macroeconomic sensitivity and fluctuating demand**. Orthodontic procedures, particularly for adults, are often considered discretionary healthcare spending, making them vulnerable to global economic uncertainties, recessions, and downturns. Fluctuations in foreign currency exchange rates also pose a significant headwind, as a substantial portion of Align's revenues are generated internationally. Economic issues, including inflation, geopolitical complications, and rising interest rates, have led to a "substantial slowdown in new orthodontic appointments and adult case starts in North America," directly impacting the company's revenue and necessitating restructuring efforts.

The company also faces **intellectual property and litigation risks**. While Align Technology possesses a robust portfolio of patents and actively defends its innovations, the expiration of some core Invisalign patents in 2017 increased competitive threats. Align is currently engaged in significant patent infringement lawsuits against competitors, such as Angelalign Technology, across multiple international jurisdictions including the United States, Europe, and China, to protect its patented technologies and substantial research and development investments. Additionally, the company has faced antitrust class action lawsuits, although it has received favorable rulings in some cases.

AI Analysis | Feedback

The emerging threat to Align Technology is the increasing capability and adoption by dental professionals of in-house 3D printing for the direct fabrication of clear aligners. As 3D printing technology becomes more accessible, affordable, and accurate, and alongside the development of user-friendly third-party design software, orthodontists and general practitioner dentists may choose to produce custom clear aligners for their patients directly within their own practices or through smaller, local labs. This trend could bypass Align Technology's traditional manufacturing and sales model for its Invisalign clear aligner products, thereby cutting into its primary revenue stream from the Clear Aligner segment by disintermediating Align as the central aligner manufacturer.

AI Analysis | Feedback

Align Technology's main products, Invisalign clear aligners and iTero intraoral scanners, operate within significant and growing addressable markets.

Clear Aligners Market

The global clear aligners market was estimated to be between USD 8.29 billion and USD 8.51 billion in 2025. Projections indicate substantial growth, with the market expected to reach approximately USD 56.81 billion by 2033 or USD 113.64 billion by 2035. North America consistently holds the largest share of this market, accounting for approximately 54.57% in 2025. The U.S. clear aligners market alone was valued at USD 2.17 billion in 2023 and is projected to reach USD 14.83 billion by 2033.

Intraoral Scanners Market

The global intraoral scanners market was valued between USD 770.4 million and USD 824.70 million in 2025. This market is forecasted to grow to approximately USD 1.68 billion by 2035 or USD 1.6 billion by 2035. North America dominated the intraoral scanners market in 2025. Specifically, the North American dental intraoral scanners market was valued at USD 277.37 million in 2024 and is anticipated to reach USD 814.96 million by 2033.

AI Analysis | Feedback

Align Technology (ALGN) is expected to drive future revenue growth over the next two to three years through several key strategies:

  1. Global Expansion and Increased Adoption of Clear Aligners Across Patient Segments: Align Technology anticipates continued growth by expanding the adoption of its Invisalign clear aligners across different patient demographics, including teenagers, younger patients (Invisalign First), and adults. This expansion is observed globally, particularly in under-penetrated international markets such as the Asia Pacific (APAC) and EMEA regions, with China identified as a significant opportunity. The company also expects higher utilization of Invisalign among orthodontists transitioning from traditional methods. Additionally, the expansion of the Invisalign Doctor Subscription Program (DSP) for touch-up cases is contributing to this growth.
  2. Innovation and Market Penetration of Imaging Systems and CAD/CAM Services: The launch and ramp-up of new technologies, such as the iTero Lumina intraoral scanner, are crucial drivers. Align Technology is also focusing on expanding restorative workflows for its iTero Lumina scanners and introducing new products like the Invisalign Palatal Expander System, which has broad patient applicability. Strategic investments in areas like AI-driven treatment planning and direct 3D printing, through acquisitions like Cubicure GmbH, are expected to further enhance their digital dentistry offerings and drive revenue in the Scanners and Services segment.
  3. Strengthening Partnerships and Engagement with Dental Service Organizations (DSOs): Align Technology is strategically focusing on Dental Service Organizations (DSOs) as a significant channel for growth. The company has observed double-digit growth from DSOs across North America, Latin America, APAC, and Europe. By strengthening ties and standardizing workflows with DSOs, Align aims to broaden its reach within the dental community and increase the adoption and utilization of its products and services.

AI Analysis | Feedback

Share Repurchases

  • Align Technology authorized a new $1.0 billion stock repurchase program in May 2025, which is expected to be executed over the next three years.
  • The company completed a previous $1.0 billion stock repurchase program, authorized in January 2023, by May 1, 2025.
  • Actual share repurchases amounted to $600 million in 2023, $353 million in 2024, and $465.9 million in 2025.

Share Issuance

  • Align Technology's executives and employees, including the EVP Global HR and the President and CEO, received and vested equity awards, leading to the acquisition of shares through derivative exercises or conversions between 2022 and 2025.
  • A shareholder filed a notice in February 2026 for the proposed sale of 7,969 common shares, which were acquired through performance stock unit vests in 2022, 2023, and 2024.

Inbound Investments

  • As of December 31, 2025, Capital International Investors held a 6.8% passive ownership stake in Align Technology, beneficially owning 4,881,512 shares.

Outbound Investments

  • In the first quarter of 2024, Align Technology completed the acquisition of Cubicure GmbH, a company specializing in direct 3D printing solutions, to support its next-generation aligner manufacturing.

Capital Expenditures

  • Capital expenditures were $401.1 million in 2021, $291.9 million in 2022, $177.7 million in 2023, and $115.6 million in 2024.
  • For fiscal year 2025, capital expenditures are estimated to be between $100 million and $125 million, primarily allocated to technology upgrades and maintenance. Forecasted capital expenditures for fiscal 2026 are expected to be between $125 million and $150 million, focusing on technology upgrades, additional manufacturing capacity, and maintenance.
  • In the second half of 2025, the company planned to optimize its manufacturing footprint and dispose of certain capital assets as it transitions to next-generation manufacturing technologies and increases automation, expecting one-time charges of approximately $150 million to $170 million, with about $40 million in cash outlays.

Better Bets vs. Align Technology (ALGN)

Peer Outperformance in Health Care Supplies

ALGN has trailed 82% of its 11 Health Care Supplies peers over 5Y. Among the peers that beat it are HAE, WST and NVST. Health Care Supplies ranks 6th of 10 industries in Health Care by median 5Y return. The sector’s gains have largely come from elsewhere.
Share of Health Care Supplies constituents that ALGN has outperformed, by holding period. Peers without a full price history over a given window are excluded from that window.
1Y
36%
of 11 industry peers · 15.8% return
3Y
18%
of 11 industry peers · -52.1% return
5Y
18%
of 11 industry peers · -75.3% return
Health Care Supplies peers with revenue growth within 4pp of ALGN's that beat it on at least 2 of 3 windows, and by at least 20pp over 5Y. Growth is matched by construction, so the gap is largely a re-rating gap. The multiple column is the context for it.
Ticker Name Rev Growth 3Y Avg P/E 1Y3Y5Y 5Y Gap
ALGN Align Technology 3.5% 29.0x 15.8%-52.1%-75.3%
HAE Haemonetics 3.6% 49.3x 97.0%23.2%81.3% +157pp
WST West Pharmaceutical Services 5.2% 43.4x 43.0%-9.9%-21.5% +54pp
NVST Envista 3.6% 47.4x 33.9%-14.9%-30.7% +45pp
COO Cooper Companies 7.3% 62.7x 3.0%-17.9%-31.4% +44pp
Price returns, excluding dividends. P/E shown for context only and not used for matching.
Median price return by industry across the Health Care sector, ranked by 5Y. Health Care Supplies is ALGN's own industry. Use this to see which corners of the sector have carried the returns.
Industry Names 1Y med3Y med5Y med Top 3 by 5Y
Health Care Distributors 7 9.7%79.7%140.2% CAH 411% · MCK 348% · COR 179%
Health Care Services 20 20.0%41.9%9.5% HIMS 302% · RDNT 143% · DGX 72%
Managed Health Care 8 33.2%-3.6%1.3% OSCR 142% · HQY 64% · ELV 14%
Health Care Facilities 24 11.9%-3.3%-15.7% THC 289% · NHC 263% · ENSG 132%
Health Care Equipment 51 -2.3%-9.2%-18.9% POCI 10738% · UFPT 396% · GKOS 288%
Health Care Supplies ← 12 38.3%-12.4%-27.5% LNTH 314% · HAE 81% · MMSI 31%
Pharmaceuticals 63 3.1%-1.7%-31.9% LQDA 2959% · INDV 1388% · ETON 1385%
Life Sciences Tools & Services 108 -8.4%-32.7%-70.6% SNWV 1953% · ELMD 259% · MEDP 235%
Health Care Technology 20 -28.4%-53.8%-73.9% SPOK 37% · HSTM -2% · VEEV -24%
Biotechnology 365 6.6%-27.4%-77.2% BRTX 106400% · DNTH 1803% · CELZ 1443%
Median of constituents with a full price history over each window. Top names are unfiltered by size in this render.

Latest Trefis Analyses

Recent Active Movers

Peer Comparisons

Peers to compare with:

Financials

ALGNNVSTXRAYHSICDDDMedian
NameAlign Te.Envista Dentsply.Henry Sc.3D Syste. 
Mkt Price167.9127.8211.1189.233.4427.82
Mkt Cap12.04.52.210.10.54.5
Rev LTM4,1402,8563,64313,6023883,643
Op Inc LTM652297184778-65297
FCF LTM634248143513-52248
FCF 3Y Avg557264215447-76264
CFO LTM756303319700-42319
CFO 3Y Avg670309376635-60376

Growth & Margins

ALGNNVSTXRAYHSICDDDMedian
NameAlign Te.Envista Dentsply.Henry Sc.3D Syste. 
Rev Chg LTM4.4%11.9%-0.8%6.5%-6.2%4.4%
Rev Chg 3Y Avg3.5%3.6%-2.5%2.6%-9.0%2.6%
Rev Chg Q4.3%7.1%-4.1%6.7%-0.3%4.3%
QoQ Delta Rev Chg LTM1.1%1.7%-1.0%1.6%-0.1%1.1%
Op Inc Chg LTM2.3%62.9%-27.0%0.9%44.0%2.3%
Op Inc Chg 3Y Avg4.9%3.7%-12.4%0.2%16.9%3.7%
Op Mgn LTM15.8%10.4%5.1%5.7%-16.7%5.7%
Op Mgn 3Y Avg16.4%8.7%6.3%5.5%-22.5%6.3%
QoQ Delta Op Mgn LTM0.6%1.0%-0.7%0.1%0.3%0.3%
CFO/Rev LTM18.3%10.6%8.8%5.1%-10.9%8.8%
CFO/Rev 3Y Avg16.6%11.7%10.0%4.9%-14.3%10.0%
FCF/Rev LTM15.3%8.7%3.9%3.8%-13.5%3.9%
FCF/Rev 3Y Avg13.8%10.0%5.7%3.5%-17.9%5.7%

Valuation

ALGNNVSTXRAYHSICDDDMedian
NameAlign Te.Envista Dentsply.Henry Sc.3D Syste. 
Mkt Cap12.04.52.210.10.54.5
P/S2.91.60.60.71.31.3
P/Op Inc18.415.212.113.0-7.913.0
P/EBIT18.416.7-8.714.2-13.814.2
P/E29.047.4-4.125.1-9.325.1
P/CFO15.914.97.014.5-12.114.5
Total Yield3.4%2.1%-20.3%4.0%-10.7%2.1%
Dividend Yield0.0%0.0%4.3%0.0%0.0%0.0%
FCF Yield 3Y Avg4.0%7.9%6.1%5.1%-25.0%5.1%
D/E0.00.41.00.40.30.4
Net D/E-0.10.10.90.40.00.1

Returns

ALGNNVSTXRAYHSICDDDMedian
NameAlign Te.Envista Dentsply.Henry Sc.3D Syste. 
1M Rtn-5.0%4.0%-20.9%1.6%27.9%1.6%
3M Rtn8.2%20.7%14.1%22.4%28.8%20.7%
6M Rtn-10.3%-0.9%-10.7%15.6%67.8%-0.9%
12M Rtn15.8%33.9%-17.6%32.7%64.6%32.7%
3Y Rtn-52.1%-14.9%-67.7%16.6%-46.8%-46.8%
1M Excs Rtn-7.4%1.3%-20.8%0.2%27.5%0.2%
3M Excs Rtn1.9%16.3%9.2%18.9%17.7%16.3%
6M Excs Rtn-22.7%-13.3%-23.1%3.2%55.4%-13.3%
12M Excs Rtn-1.4%15.5%-36.8%12.3%48.5%12.3%
3Y Excs Rtn-124.7%-89.0%-141.2%-55.9%-123.6%-123.6%

Comparison Analyses

Financials

Segment Financials

Revenue by Segment
$ Mil20252024202320222021
Clear Aligner3,2453,2303,1993,0733,247
Systems and Services790769663662706
Total4,0353,9993,8623,7353,953


Operating Income by Segment
$ Mil20252024202320222021
Clear Aligner1,0351,1421,1821,1341,326
Systems and Services306269191180259
Unallocated corporate expenses-795-804-730-672-609
Total546608643643976


Assets by Segment
$ Mil2011
Clear Aligner469
Scanners and CAD/CAM Services180
Total649


Price Behavior

Price Behavior
Market Price$167.91 
Market Cap ($ Bil)12.0 
First Trading Date01/30/2001 
Distance from 52W High-15.0% 
   50 Days200 Days
DMA Price$175.65$169.26
DMA Trendupup
Distance from DMA-4.4%-0.8%
 3M1YR
Volatility45.7%39.9%
Downside Capture132.91143.32
Upside Capture141.74130.00
Correlation (SPY)29.1%45.5%
ALGN Betas & Captures as of 7/31/2026

 1M2M3M6M1Y3Y
Beta0.030.670.911.401.421.40
Up Beta-2.09-0.510.071.461.701.52
Down Beta0.020.930.851.470.931.07
Up Capture70%85%99%138%149%174%
Bmk +ve Days11223567138427
Stock +ve Days11213064125367
Down Capture67%100%135%134%145%110%
Bmk -ve Days11212859114326
Stock -ve Days11223362127385

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with ALGN
ALGN18.0%39.8%0.50-
Sector ETF (XLV)26.3%15.5%1.3137.2%
Equity (SPY)20.4%12.8%1.1745.6%
Gold (GLD)29.8%28.5%0.9116.0%
Commodities (DBC)40.2%20.2%1.56-20.3%
Real Estate (VNQ)13.1%13.9%0.6539.8%
Bitcoin (BTCUSD)-45.4%42.7%-1.3019.5%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with ALGN
ALGN-24.3%49.9%-0.37-
Sector ETF (XLV)6.6%15.0%0.2539.4%
Equity (SPY)13.1%17.2%0.5952.7%
Gold (GLD)19.8%18.6%0.877.2%
Commodities (DBC)9.8%19.6%0.395.1%
Real Estate (VNQ)2.4%18.9%0.0242.9%
Bitcoin (BTCUSD)7.1%52.6%0.3225.6%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with ALGN
ALGN6.4%49.3%0.32-
Sector ETF (XLV)10.4%16.7%0.5147.3%
Equity (SPY)15.2%17.9%0.7255.5%
Gold (GLD)12.1%16.2%0.616.3%
Commodities (DBC)7.8%18.1%0.3514.4%
Real Estate (VNQ)4.8%20.7%0.2043.8%
Bitcoin (BTCUSD)59.9%66.0%1.0014.7%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Short Interest

Short Interest: As Of Date7312026
Short Interest: Shares Quantity4.2 Mil
Short Interest: % Change Since 7152026-12.9%
Average Daily Volume1.1 Mil
Days-to-Cover Short Interest4.0 days
Basic Shares Quantity71.5 Mil
Short % of Basic Shares5.9%

Earnings Returns History

Updated 8/7/2026
Expand for More
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
7/29/2026-3.7%-2.9% 
4/29/2026-1.3%-2.5%-1.9%
2/4/20268.9%22.4%7.9%
10/29/20254.9%4.0%11.2%
7/30/2025-36.6%-32.8%-30.7%
4/30/20252.0%-0.6%4.4%
2/5/20250.9%-5.1%-19.7%
10/23/20244.2%1.5%9.9%
...
SUMMARY STATS   
# Positive131211
# Negative111212
Median Positive7.5%9.9%9.9%
Median Negative-7.7%-8.3%-12.8%
Max Positive35.0%30.9%31.4%
Max Negative-36.6%-32.8%-30.7%
Collapse to Preview
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
7/29/2026-3.7%-2.9% 
4/29/2026-1.3%-2.5%-1.9%
2/4/20268.9%22.4%7.9%
10/29/20254.9%4.0%11.2%
7/30/2025-36.6%-32.8%-30.7%
4/30/20252.0%-0.6%4.4%
2/5/20250.9%-5.1%-19.7%
10/23/20244.2%1.5%9.9%
7/24/2024-7.7%-5.3%-6.6%
4/24/2024-1.0%-9.3%-19.6%
1/31/20242.3%6.5%12.2%
10/25/2023-24.9%-27.8%-13.5%
7/26/202313.4%8.1%3.2%
4/26/2023-10.4%-14.5%-21.0%
2/1/202327.4%18.5%18.4%
10/26/2022-18.1%-19.2%-12.2%
7/27/20227.5%9.0%4.0%
4/27/2022-15.5%-13.7%-23.7%
2/2/2022-0.5%8.0%-8.1%
10/27/20214.5%11.5%4.9%
7/28/20218.9%13.9%12.0%
4/28/2021-1.5%-7.2%-2.2%
2/3/202112.6%10.9%-1.8%
10/21/202035.0%30.9%31.4%
SUMMARY STATS   
# Positive131211
# Negative111212
Median Positive7.5%9.9%9.9%
Median Negative-7.7%-8.3%-12.8%
Max Positive35.0%30.9%31.4%
Max Negative-36.6%-32.8%-30.7%

SEC Filings

Expand for More
Report DateFiling DateFiling
06/30/202608/05/202610-Q
03/31/202605/06/202610-Q
12/31/202502/27/202610-K
09/30/202511/05/202510-Q
06/30/202508/06/202510-Q
03/31/202505/08/202510-Q
12/31/202402/28/202510-K
09/30/202411/05/202410-Q
06/30/202408/02/202410-Q
03/31/202405/03/202410-Q
12/31/202302/28/202410-K
09/30/202311/03/202310-Q
06/30/202308/04/202310-Q
03/31/202305/05/202310-Q
12/31/202202/27/202310-K
09/30/202211/04/202210-Q
Collapse to Preview
Report DateFiling DateFiling
06/30/202608/05/202610-Q
03/31/202605/06/202610-Q
12/31/202502/27/202610-K
09/30/202511/05/202510-Q
06/30/202508/06/202510-Q
03/31/202505/08/202510-Q
12/31/202402/28/202510-K
09/30/202411/05/202410-Q
06/30/202408/02/202410-Q
03/31/202405/03/202410-Q
12/31/202302/28/202410-K
09/30/202311/03/202310-Q
06/30/202308/04/202310-Q
03/31/202305/05/202310-Q
12/31/202202/27/202310-K
09/30/202211/04/202210-Q
06/30/202208/04/202210-Q
03/31/202205/05/202210-Q
12/31/202102/25/202210-K
09/30/202111/02/202110-Q
06/30/202108/04/202110-Q
03/31/202105/05/202110-Q
12/31/202002/26/202110-K
09/30/202010/30/202010-Q
06/30/202007/31/202010-Q
03/31/202005/05/202010-Q
12/31/201902/28/202010-K
09/30/201910/31/201910-Q

Recent Forward Guidance

Updated 7/30/2026

Latest: Q2 2026 Earnings Reported 7/29/2026

Forward GuidanceGuidance Change
MetricLowMidHigh% Chg% DeltaChangePrior
Q3 2026 Revenue1.00 Bil1.01 Bil1.02 Bil-3.8% Lower NewGuidance: 1.05 Bil for Q2 2026
Q3 2026 GAAP Gross Margin67.5%68.0%68.5%   
Q3 2026 GAAP Operating Margin13.5%14.25%15.0% -2.2%Lower NewGuidance: 16.4% for Q2 2026
2026 Revenue Growth3.0%3.5%4.0% 0AffirmedGuidance: 3.5% for 2026
2026 GAAP Gross Margin70.2%70.35%70.5%   
2026 GAAP Operating Margin15.1%15.35%15.6% -2.6%LoweredGuidance: 18.0% for 2026
2026 Capital Expenditures125.00 Mil137.50 Mil150.00 Mil0 AffirmedGuidance: 137.50 Mil for 2026
2026 Share Repurchases400.00 Mil450.00 Mil500.00 Mil125.0% RaisedGuidance: 200.00 Mil for 2026

Prior: Q1 2026 Earnings Reported 4/29/2026

Forward GuidanceGuidance Change
MetricLowMidHigh% Chg% DeltaChangePrior
Q2 2026 Revenue1.04 Bil1.05 Bil1.06 Bil2.9% Higher NewActual: 1.02 Bil for Q1 2026
Q2 2026 Revenue Growth3.0%4.0%5.0% 0Same NewActual: 4.0% for Q1 2026
Q2 2026 GAAP Operating Margin 16.4%  3.8%Higher NewActual: 12.6% for Q1 2026
Q2 2026 Non-GAAP Operating Margin 21.5%  2.0%Higher NewActual: 19.5% for Q1 2026
2026 Revenue Growth3.0%3.5%4.0% 0AffirmedGuidance: 3.5% for 2026
2026 GAAP Operating Margin 18.0%  0AffirmedGuidance: 18.0% for 2026
2026 Non-GAAP Operating Margin 23.7%  0AffirmedGuidance: 23.7% for 2026
2026 Capital Expenditures125.00 Mil137.50 Mil150.00 Mil0 AffirmedGuidance: 137.50 Mil for 2026
2026 Share Repurchases 200.00 Mil    

Q4 2025 Earnings Reported 2/4/2026

Forward GuidanceGuidance Change
MetricLowMidHigh% Chg% DeltaChangePrior
Q1 2026 Revenue1.01 Bil1.02 Bil1.03 Bil-1.4% Lower NewActual: 1.03 Bil for Q4 2025
Q1 2026 Revenue Growth3.0%4.0%5.0%   
Q1 2026 GAAP Operating Margin12.4%12.6%12.8%-19.0%-3.0%Lower NewActual: 15.55% for Q4 2025
Q1 2026 Non-GAAP Operating Margin 19.5% -25.0%-6.5%Lower NewActual: 26.0% for Q4 2025
2026 Revenue Growth3.0%3.5%4.0% 3.5%Higher NewActual: 0.0% for 2025
2026 GAAP Operating Margin 18.0% 31.4%4.3%Higher NewActual: 13.7% for 2025
2026 Non-GAAP Operating Margin 23.7% 5.3%1.2%Higher NewActual: 22.5% for 2025
2026 Capital Expenditures125.00 Mil137.50 Mil150.00 Mil37.5% Higher NewActual: 100.00 Mil for 2025

Q3 2025 Earnings Reported 10/29/2025

Forward GuidanceGuidance Change
MetricLowMidHigh% Chg% DeltaChangePrior
Q4 2025 Revenue1.02 Bil1.03 Bil1.04 Bil6.2% Higher NewGuidance: 975.00 Mil for Q3 2025
Q4 2025 GAAP Gross Margin65.5%65.75%66.0% 1.2%Higher NewGuidance: 64.5% for Q3 2025
Q4 2025 Non-GAAP Gross Margin 71.0%    
Q4 2025 GAAP Operating Margin15.3%15.55%15.8% 4.6%Higher NewGuidance: 11.0% for Q3 2025
Q4 2025 Non-GAAP Operating Margin 26.0%    
2025 Clear Aligner Volume Growth 5.0%    
2025 Revenue Growth 0.0%    
2025 GAAP Operating Margin13.6%13.7%13.8% 0.2%RaisedGuidance: 13.5% for 2025
2025 Non-GAAP Operating Margin 22.5%    
2025 Capital Expenditures 100.00 Mil -11.1% LoweredGuidance: 112.50 Mil for 2025

Insider Activity

Updated 5/22/2026
Expand for More
#OwnerTitleHoldingActionFiling DatePriceSharesTransacted
Value
Value of
Held Shares
Form
1Morici, JohnEVP, CHIEF FINANCIAL OFFICERDirectSell2202026189.317,9691,508,6461,559,382Form
2Hogan, Joseph MPRESIDENT AND CEODirectBuy8012025131.497,576996,13124,317,512Form
3Coletti, Julie AnnEVP, CHIEF LEGAL & REGULATORYDirectBuy8012025109.66424,606779,672Form
Collapse to Preview
#OwnerTitleHoldingActionFiling DatePriceSharesTransacted
Value
Value of
Held Shares
Form
1Morici, JohnEVP, CHIEF FINANCIAL OFFICERDirectSell2202026189.317,9691,508,6461,559,382Form
2Hogan, Joseph MPRESIDENT AND CEODirectBuy8012025131.497,576996,13124,317,512Form
3Coletti, Julie AnnEVP, CHIEF LEGAL & REGULATORYDirectBuy8012025109.66424,606779,672Form

Investor Activity (13F)

Updated Aug 19, 2026
13F holdings as of Mar 31, 2026 (Q1 2026)

Active managers (13F portfolio over $250M, at least 3 holdings) with a position over $5M that is either over 10% of their portfolio or held in a concentrated book of 50 or fewer total positions. Index/ETF, sovereign, bank, community-bank and charitable/donor-advised filers are excluded.

Active ManagerValue% of PortfolioTotal PositionsQoQFiling
Senvest Management, LLC$129.4 Mil4.3%49ADD +8.6%13F
Ruane, Cunniff & Goldfarb L.P.$206.8 Mil3.4%50Hold13F
California First Leasing Corp$7.7 Mil2.5%39Hold13F
Defilade Capital Management, L.P.$11.5 Mil1.6%31TRIM -47.4%13F
Active ManagerValue% of PortfolioTotal PositionsQoQFiling
Senvest Management, LLC$129.4 Mil4.3%49ADD +8.6%13F
Active ManagerValue% of PortfolioTotal PositionsQoQFiling
Defilade Capital Management, L.P.$11.5 Mil1.6%31TRIM -47.4%13F
Active ManagerValue% of PortfolioTotal PositionsQoQFiling
Ruane, Cunniff & Goldfarb L.P.$206.8 Mil3.4%50Hold13F
Senvest Management, LLC$129.4 Mil4.3%49ADD +8.6%13F
Defilade Capital Management, L.P.$11.5 Mil1.6%31TRIM -47.4%13F
California First Leasing Corp$7.7 Mil2.5%39Hold13F
Core Cache Last Updated: 8/18/2026